CL2020003143A1 - Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria - Google Patents

Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Info

Publication number
CL2020003143A1
CL2020003143A1 CL2020003143A CL2020003143A CL2020003143A1 CL 2020003143 A1 CL2020003143 A1 CL 2020003143A1 CL 2020003143 A CL2020003143 A CL 2020003143A CL 2020003143 A CL2020003143 A CL 2020003143A CL 2020003143 A1 CL2020003143 A1 CL 2020003143A1
Authority
CL
Chile
Prior art keywords
ascorbic acid
treatment
combination
antiparasitic agent
quinone compounds
Prior art date
Application number
CL2020003143A
Other languages
English (en)
Inventor
Sueli De Oliveira Silva Lautenschlager
Vania Cristina Desoti
Celso Vataru Nakamura
Valdecir Farias Ximenes
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of CL2020003143A1 publication Critical patent/CL2020003143A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente proporciona un método para tratar, prevenir o aliviar uno o más síntomas de la enfermedad de Chagas que comprende administrar: (i) ácido ascórbico; (ii) un compuesto de quinona, un enantiómero simple, una mezcla de enantiómeros, o una mezcla de diastereómeros de (i) y de (ii), o una sal, solvato, hidrato o profármaco farmacéuticamente aceptable de (i) y de (ii); y (iii) un agente antiparasitario.
CL2020003143A 2018-06-06 2020-12-03 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria CL2020003143A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862681500P 2018-06-06 2018-06-06

Publications (1)

Publication Number Publication Date
CL2020003143A1 true CL2020003143A1 (es) 2021-06-11

Family

ID=68769906

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003143A CL2020003143A1 (es) 2018-06-06 2020-12-03 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Country Status (12)

Country Link
US (2) US11872233B2 (es)
AR (1) AR115493A1 (es)
AU (1) AU2019282657B2 (es)
BR (1) BR112020024807A2 (es)
CA (1) CA3101331C (es)
CL (1) CL2020003143A1 (es)
CR (1) CR20200636A (es)
ES (1) ES2811674B2 (es)
MX (1) MX2020013076A (es)
PE (1) PE20212333A1 (es)
PY (1) PY1944026A (es)
WO (1) WO2019236656A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006593A (es) 2016-12-06 2019-09-13 Ic Medtech Corp Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease
CN115361945B (zh) * 2020-03-31 2024-11-12 浙江养生堂天然药物研究所有限公司 药物组合及其用途
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
CN105232532A (zh) 2009-07-20 2016-01-13 萨马保健系统公司 维生素c和维生素k的组合及其用途
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
EP3490543A4 (en) * 2016-08-01 2020-04-01 IC-Medtech Corp. ASCORBIC ACID, QUINONE COMPOUND AND SODIUM GLUCOSE CO-TRANSPORTER INHIBITOR FOR THE TREATMENT OF CANCER.
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Also Published As

Publication number Publication date
PE20212333A1 (es) 2021-12-14
AR115493A1 (es) 2021-01-27
CR20200636A (es) 2021-06-10
US20210361666A1 (en) 2021-11-25
ES2811674B2 (es) 2024-02-07
US20240165084A1 (en) 2024-05-23
ES2811674R1 (es) 2021-09-20
US12295957B2 (en) 2025-05-13
BR112020024807A2 (pt) 2021-03-02
US11872233B2 (en) 2024-01-16
CA3101331C (en) 2023-12-19
AU2019282657B2 (en) 2024-10-17
ES2811674A2 (es) 2021-03-12
AU2019282657A1 (en) 2020-12-10
CA3101331A1 (en) 2019-12-12
WO2019236656A1 (en) 2019-12-12
PY1944026A (es) 2021-10-27
MX2020013076A (es) 2021-03-02

Similar Documents

Publication Publication Date Title
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
DOP2025000044A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
PH12021550713A1 (en) Medicament for the treatment of chronic cough
AR119159A1 (es) Tratamientos de angioedema
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
ECSP19048402A (es) Compuestos de ácido ascórbico y quinona para el tratamiento de la enfermedad de chagas
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres
AR102030A1 (es) Métodos para tratar enfermedades del hígado